Treatment of CMV Retinitis: Induction: The recommended dose is 900 mg (two 450 mg tablets)
twice a day for 21 days. Maintenance: Following induction treatment, or in adult
patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg
tablets) once a day.
Prevention of CMV Disease:
For adult patients who have received a heart or kidney-pancreas transplant, the
recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10
days of transplantation until 100 days post-transplantation.
For adult patients who have received a kidney transplant, the recommended dose
is 900 mg (two 450 mg tablets) once a day starting within 10 days of
transplantation until 200 days post-transplantation.
Manufacturer: Valcyte should not be prescribed to patients receiving
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read